ArticleFrontiers in nutrition2025
Magnesium depletion score is a risk factor for all-cause, cancer and cardiovascular disease mortality in cancer survivors: evidence from two prospective cohort studies.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer survivors face significant mortality risks, including from cardiovascular disease (CVD) and cancer. Magnesium depletion score (MDS) is a prognostic biomarker, but its prognostic value in cancer survivors is unknown. Methods: This prospective study utilizes data from two distinct cohorts: the National Health and Nutrition Examination Survey (NHANES) and the Shaanxi Provincial People's Hospital. We analyzed 3,528 cancer survivors from NHANES (1999-2018) and 473 patients from the hospital cohort. Associations between MDS (0, 1, 2, ≥3) and all-cause, cancer-specific, and CVD mortality were assessed using weighted multivariate Cox regression, Kaplan-Meier analysis and Fine-Gray competing risk model. Predictive accuracy was evaluated using time-dependent ROC curves. Results: During follow-up (median 165 months for NHANES), higher MDS (≥3) was significantly associated with increased mortality risk after full adjustment: all-cause (HR = 2.48, 95% CI: 1.86-3.29), cancer (HR = 2.17, 95% CI: 1.44-3.26), and CVD (HR = 3.89, 95% CI: 1.91-7.91) compared to MDS = 0 (all Conclusion: Higher MDS is a strong, independent predictor of increased all-cause, cancer-specific, and CVD mortality risk among cancer survivors. MDS provides valuable prognostic information and could aid in risk stratification for personalized survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.